Asian Paints

2859.7 -14.70

Cipla

1525.6 -5.70

Eicher Motors

7085 31.50

Nestle India

1261.5 0.40

Grasim Inds

2734.9 -4.50

Hindalco Inds.

810.6 2.20

Hind. Unilever

2486 19.40

ITC

403.65 -0.60

Trent

4236 -14.40

Larsen & Toubro

4065.5 -4.10

M & M

3746.7 -10.60

Reliance Industr

1573.8 6.30

Tata Consumer

1167.6 -4.80

Tata Motors PVeh

360.65 3.85

Tata Steel

168.16 0.20

Wipro

249.64 0.11

Apollo Hospitals

7347 11.50

Dr Reddy's Labs

1259.5 0.70

Titan Company

3866.6 -41.10

SBI

984.5 5.50

Shriram Finance

855.8 4.15

Bharat Electron

414.6 2.85

Kotak Mah. Bank

2161.4 37.00

Infosys

1561.8 1.70

Bajaj Finance

1030 -7.50

Adani Enterp.

2289.6 9.40

Sun Pharma.Inds.

1816.5 -15.10

JSW Steel

1161.5 1.20

HDFC Bank

1008.7 1.10

TCS

3134 -3.50

ICICI Bank

1395.8 7.00

Power Grid Corpn

270.15 0.20

Maruti Suzuki

15922 22.00

Axis Bank

1278.4 -1.30

HCL Technologies

1633.9 9.70

O N G C

244.89 1.64

NTPC

326.25 -0.20

Coal India

376.25 0.10

Bharti Airtel

2099.5 -2.10

Tech Mahindra

1512.7 -4.60

Jio Financial

306 -0.20

Adani Ports

1539.8 22.90

HDFC Life Insur.

762.15 -2.15

SBI Life Insuran

1958 -8.00

Max Healthcare

1161.1 -1.70

UltraTech Cem.

11575 -25.00

Bajaj Auto

9120 46.50

Bajaj Finserv

2094.1 0.10

Interglobe Aviat

5865 -36.50

Eternal Ltd

302.1 2.00

Corporate News - Detailed News Back
Lupin receives USFDA approval for biosimilar Armlupeg' (pegfilgrastim-unne)
01-Dec-25   09:16 Hrs IST
Lupin announced that the United States Food and Drug Administration (U.S. FDA) has approved Armlupeg' (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta' (pegfilgrastim) 6 mg/0.6 mL injection.

The product will be manufactured at Lupin's Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval.

Armlupeg' is indicated for:

 - Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

 - Increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Powered by Capital Market - Live News


DJIA 47737.43
289.30 0.61%
S&P 500 6869.48
35.87 0.52%
HANG SENG 25858.90
-87.04 -0.34%
NIKKEI 225 50220.95
53.85 0.11%
FTSE 100 9721.02
27.09 0.28%
NIFTY 26242.40
39.45 0.15%
×
Ask Your Question
close
refresh